Standout Papers

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients 2006 2026 2012 2019 740
  1. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients (2006)
    Animesh Pardanani, Ross L. Levine et al. Blood
  2. Anthracycline Dose Intensification in Acute Myeloid Leukemia (2009)
    Hugo F. Fernández, Zhuoxin Sun et al. New England Journal of Medicine
  3. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study (2006)
    Adele K. Fielding, Susan Richards et al. Blood
  4. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) (2007)
    Anthony H. Goldstone, Susan Richards et al. Blood
  5. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007)
    Hagop M. Kantarjian, Francis J. Giles et al. Blood
  6. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation (2012)
    Paul J. Martin, J. Douglas Rizzo et al. Biology of Blood and Marrow Transplantation
  7. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022)
    Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology
  8. Palliative Care for Patients With Cancer: ASCO Guideline Update (2024)
    Justin J. Sanders, Sarah Temin et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 5 from Science/Nature 75 standout
Sub-graph 1 of 17

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Acute myeloid leukaemia
2023 Standout

Works of Mark R. Litzow being referenced

Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience
2018
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
Mark R. Litzow 11567 4734 4715 5368 585 18.3k
Daniel J. DeAngelo 8805 3832 4208 6062 438 15.9k
Hervé Dombret 13182 3576 5915 7064 369 18.4k
Ravi Bhatia 8749 4278 4389 4683 453 21.2k
Nicolaus Kröger 11615 3763 2576 3350 573 16.4k
Franco Mandelli 8904 3560 3552 4750 482 14.9k
Gerhard Ehninger 13344 5102 3743 6007 677 24.5k
Sherry Pierce 10152 4599 4099 4745 425 14.3k
Charles A. Schiffer 15190 6356 4449 6682 276 21.5k
Sergio Amadori 9706 3635 2913 4055 359 15.2k
Aloïs Gratwohl 16813 4651 4332 2713 509 23.3k

All Works

Loading papers...

Rankless by CCL
2026